• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

多中心、开放性、非随机、非干预性观察性研究,评估使用双时相门冬胰岛素起始治疗的安全性。

Multicenter, open-label, non-randomized, non-interventional observational study of safety of treatment initiation with a biphasic insulin aspart.

机构信息

Medical University of Gdańsk, Department of Hypertension and Diabetology, Debinki 7, 80-211 Gdansk, Poland.

出版信息

Expert Opin Drug Saf. 2013 Mar;12(2):137-44. doi: 10.1517/14740338.2013.761971. Epub 2013 Jan 7.

DOI:10.1517/14740338.2013.761971
PMID:23289795
Abstract

BACKGROUND

Type 2 diabetes mellitus is characterized by hyperglycaemia. Incidence and progression of microvascular complications have been shown to undergo reduction with lowered glucose levels.

METHODS

This is an open-label, non-randomized, non-interventional, observational study of safety and efficacy of BiAsp 30, enrolling 2223 patients with type 2 diabetes mellitus. Patients previously treated with oral antidiabetic drugs and/or human insulin were recruited, provided they had been hospitalized for at least 3 days. Data were collected during a single multi-stage visit lasting up to 6 days, during the patient's hospitalization period. A mild hypoglycaemic episode was defined as blood glucose measurement < 56 mg/dL (3.1 mmol/L). A severe hypoglycaemia was hypoglycaemic episode requiring assistance of another person.

RESULTS

The total number of hypoglycaemic episodes decreased over time of follow-up. The intensity of severe hypoglycaemic episodes decreased by almost a third from day to day (IRR = 0.64, 95%, p < 0.001). However, intensity of mild hypoglycaemic episodes was the same over the subsequent days of follow-up (IRR = 0.97, p > 0.1). Mean blood glucose concentration decreased from 202.0 mg/dL to 157.8 mg/dL after 3 days and to 138.3 mg/dL after 6 days (p < 0.001).

CONCLUSION

This study highlights the safety, efficacy and ease of initiation of insulin BiAsp 30 therapy for treatment of type 2 diabetes mellitus.

摘要

背景

2 型糖尿病的特征是高血糖。已经表明,降低血糖水平可以减少微血管并发症的发生和进展。

方法

这是一项针对安全性和疗效的开放标签、非随机、非干预性、观察性研究,共纳入 2223 例 2 型糖尿病患者。入组患者之前接受过口服降糖药和/或人胰岛素治疗,前提是他们至少住院 3 天。数据在单次多阶段就诊期间收集,持续长达 6 天,在此期间患者住院。轻度低血糖发作定义为血糖测量值<56mg/dL(3.1mmol/L)。严重低血糖是指需要他人协助的低血糖发作。

结果

随着随访时间的延长,低血糖发作的总次数逐渐减少。严重低血糖发作的强度每天下降近三分之一(IRR=0.64,95%,p<0.001)。然而,随后几天的轻度低血糖发作强度相同(IRR=0.97,p>0.1)。治疗 3 天后,平均血糖浓度从 202.0mg/dL 降至 157.8mg/dL,治疗 6 天后降至 138.3mg/dL(p<0.001)。

结论

这项研究强调了胰岛素 BiAsp 30 治疗 2 型糖尿病的安全性、疗效和起始治疗的便利性。

相似文献

1
Multicenter, open-label, non-randomized, non-interventional observational study of safety of treatment initiation with a biphasic insulin aspart.多中心、开放性、非随机、非干预性观察性研究,评估使用双时相门冬胰岛素起始治疗的安全性。
Expert Opin Drug Saf. 2013 Mar;12(2):137-44. doi: 10.1517/14740338.2013.761971. Epub 2013 Jan 7.
2
Starting or switching to biphasic insulin aspart 30 (BIAsp 30) in type 2 diabetes: a multicenter, observational, primary care study conducted in Finland.在 2 型糖尿病中起始或转换为双时相门冬胰岛素 30 治疗(BIAsp 30):一项在芬兰开展的多中心、观察性、初级保健研究。
Diabetes Res Clin Pract. 2012 Jan;95(1):10-8. doi: 10.1016/j.diabres.2011.06.006. Epub 2011 Nov 9.
3
Premixed insulin aspart 30 (BIAsp 30) versus premixed human insulin 30 (BHI 30) in gestational diabetes mellitus: a randomized open-label controlled study.预混门冬胰岛素 30(BIAsp 30)对比预混人胰岛素 30(BHI 30)治疗妊娠期糖尿病:一项随机、开放标签、对照研究。
Gynecol Endocrinol. 2012 Jul;28(7):529-32. doi: 10.3109/09513590.2011.650661. Epub 2012 Apr 3.
4
Switching from biphasic human insulin to biphasic insulin aspart 30 in type 2 diabetes: results from the ASEAN subgroup of the A₁chieve study.在 2 型糖尿病患者中,由人胰岛素双相预混制剂转换为门冬胰岛素 30 双相预混制剂:来自 A1chieve 研究东盟亚组的结果。
Diabetes Res Clin Pract. 2013 Apr;100 Suppl 1:S24-9. doi: 10.1016/S0168-8227(13)70006-8.
5
Efficacy and safety of insulin degludec/insulin aspart versus biphasic insulin aspart 30 in Chinese adults with type 2 diabetes: A phase III, open-label, 2:1 randomized, treat-to-target trial.中文 2 型糖尿病患者中德谷胰岛素/门冬胰岛素与精蛋白锌重组赖脯胰岛素 30 疗效和安全性的比较:一项 III 期、开放标签、2:1 随机、目标导向治疗的试验。
Diabetes Obes Metab. 2019 Jul;21(7):1652-1660. doi: 10.1111/dom.13703. Epub 2019 Apr 4.
6
Safety and effectiveness of biphasic insulin aspart 30 in type 2 diabetes patients switched from biphasic human insulin 30: results from the Filipino cohort of the A₁chieve study.在从人胰岛素 30 双时相转换为门冬胰岛素 30 双时相的 2 型糖尿病患者中的安全性和有效性:来自 A1chieve 研究菲律宾队列的结果。
Diabetes Res Clin Pract. 2013 Apr;100 Suppl 1:S35-40. doi: 10.1016/S0168-8227(13)70008-1.
7
Safety and effectiveness of biphasic insulin aspart 30 in a Bangladeshi subgroup of type 2 diabetic patients switched from biphasic human insulin 30: a sub-analysis of the A₁chieve study.在从双相人胰岛素 30 转换而来的孟加拉 2 型糖尿病患者亚组中,双相胰岛素门冬 30 的安全性和有效性:A₁chieve 研究的一项亚分析。
Diabetes Res Clin Pract. 2013 Apr;100 Suppl 1:S30-4. doi: 10.1016/S0168-8227(13)70007-X.
8
Comparison of exenatide with biphasic insulin aspart 30 on glucose variability in type 2 diabetes: study protocol for a randomized controlled trial.艾塞那肽与门冬胰岛素30治疗2型糖尿病血糖变异性的比较:一项随机对照试验的研究方案
Trials. 2016 Mar 24;17:160. doi: 10.1186/s13063-016-1258-8.
9
Lower rates of hypoglycemia during maintenance treatment with insulin degludec/insulin aspart versus biphasic insulin aspart 30: a combined analysis of two Phase 3a studies in type 2 diabetes.德谷胰岛素/门冬胰岛素与双相门冬胰岛素30在维持治疗期间低血糖发生率较低:两项2型糖尿病3a期研究的联合分析
J Diabetes. 2016 Sep;8(5):720-8. doi: 10.1111/1753-0407.12355. Epub 2016 Mar 6.
10
Safety and effectiveness of biphasic insulin aspart 30 in type 2 diabetes: results from the ASEAN cohort of the A₁chieve study.在 2 型糖尿病中应用双相门冬胰岛素 30 的安全性和有效性:来自 A₁chieve 研究东盟队列的结果。
Diabetes Res Clin Pract. 2013 Apr;100 Suppl 1:S3-9. doi: 10.1016/S0168-8227(13)70003-2.

引用本文的文献

1
15 Years of Experience with Biphasic Insulin Aspart 30 in Type 2 Diabetes.15 年应用双相门冬胰岛素 30 治疗 2 型糖尿病的经验。
Drugs R D. 2018 Mar;18(1):27-39. doi: 10.1007/s40268-018-0228-x.